RxDoctor Payments DataLook up a doctor →

Yaniv Berger, DO

Family Medicine · Baltimore, MDNPI 1992962369

Payments from drug & device makers

$12,957in general payments, 2019–2025

Across 790 payments — averaging $16.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$2K
  • AstraZeneca$1K
  • Lilly USA, LLC$1K
  • Amgen$1K
  • Bayer$617
  • plus $4K from 44 others

What the payments were for

  • Consulting fees$1201%
  • Food & beverage$12,59697%
  • Education$2412%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,957 in reported general payments places this provider in the 95th percentile of 1,193 family medicine providers in Maryland.

See all family medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$160,553
Medicare patients
543
Services billed
1,704

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban137$123,916
OzempicSemaglutide88$112,995
MounjaroTirzepatide68$90,274
JardianceEmpagliflozin107$87,315
FarxigaDapagliflozin Propanediol73$81,376
RybelsusSemaglutide38$67,195
TrulicityDulaglutide35$50,889
Soliqua 100-33Insulin Glargine/Lixisenatide20$34,660
KerendiaFinerenone36$29,193
XareltoRivaroxaban19$29,064
Tresiba Flextouch U-200Insulin Degludec25$27,056
JanuviaSitagliptin Phosphate18$23,980
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$14,069
Xigduo XrDapaglifloz Propaned/Metformin12$10,794
DapagliflozinDapagliflozin Propanediol13$10,339

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$2,027$180,190126 claims
Lilly USA, LLCMounjaro, Trulicity$1,283$141,163103 claims
PfizerEliquis$524$123,916137 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,487$89,09485 claims
Boehringer IngelheimJardiance$553$87,315107 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$317$34,66020 claims
BayerKerendia$617$29,19336 claims
Johnson & JohnsonXarelto$32$29,06419 claims
MerckJanuvia$232$23,98018 claims
GSKTrelegy Ellipta, Breo Ellipta$447$23,35532 claims
AbbVieLinzess$2,031$9,41214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,193 family medicine providers in Maryland.

Other family medicine in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →